Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Transarterial chemoembolization (TACE) is performed for single hepatocellular carcinoma (HCC) that are not eligible for surgery or ablation therapy. We investigated the clinical outcomes of patients with a single HCC ≤ 5 cm treated with TACE. Methods: This study analyzed 175 consecutive patients who underwent TACE as an initial treatment for single HCC ≤ 5 cm. Predictive factors for complete response (CR), recurrence after CR, and overall survival (OS) were evaluated. Results: Total 119 patients (68%) achieved CR after TACE. Tumor size < 3 cm and hepatitis B virus infection were significant predictors of CR (p < 0.05). Recurrent HCC was detected in 73 patients (61.3%) after CR. Age > 65 years and absence of liver cirrhosis were predictive factors for non-recurrence after CR (p < 0.05). The OS for all patients was 80.7 ± 5.6 months, and the 1-, 3-, and 5-year OS rates were 88.1%, 64.8%, and 49.9%, respectively. In multivariate analysis for OS, CR (hazard ratio [HR], 0.467; 95% confidence interval [CI], 0.292 to 0.747) and Child class A (HR, 0.390; 95% CI, 0.243 to 0.626) were significant factors. The OS for the CR and Child class A group were 92 and 93.6 months, respectively, and that of the non-CR and Child B, C group were 53.3 and 50.7 months, respectively (p < 0.001). Conclusions: TACE can be a valid treatment in patients with a single HCC ≤ 5 cm not suitable for curative treatment, especially in patients with Child class A and CR after TACE.
Abstract
Background/Aims: Transarterial chemoembolization (TACE) is performed for single hepatocellular carcinoma (HCC) that are not eligible for surgery or ablation therapy. We investigated the clinical outcomes of patients with a single HCC ≤ 5 cm treated with TACE. Methods: This study analyzed 175 consecutive patients who underwent TACE as an initial treatment for single HCC ≤ 5 cm. Predictive factors for complete response (CR), recurrence after CR, and overall survival (OS) were evaluated. Results: Total 119 patients (68%) achieved CR after TACE. Tumor size < 3 cm and hepatitis B virus infection were significant predictors of CR (p < 0.05). Recurrent HCC was detected in 73 patients (61.3%) after CR. Age > 65 years and absence of liver cirrhosis were predictive factors for non-recurrence after CR (p < 0.05). The OS for all patients was 80.7 ± 5.6 months, and the 1-, 3-, and 5-year OS rates were 88.1%, 64.8%, and 49.9%, respectively. In multivariate analysis for OS, CR (hazard ratio [HR], 0.467; 95% confidence interval [CI], 0.292 to 0.747) and Child class A (HR, 0.390; 95% CI, 0.243 to 0.626) were significant factors. The OS for the CR and Child class A group were 92 and 93.6 months, respectively, and that of the non-CR and Child B, C group were 53.3 and 50.7 months, respectively (p < 0.001). Conclusions: TACE can be a valid treatment in patients with a single HCC ≤ 5 cm not suitable for curative treatment, especially in patients with Child class A and CR after TACE.
참고문헌 (38)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- El-Serag HB, "Hepatocellular carcinoma and hepatitis C in the United States", Hepatology, 36(5 Suppl 1), pp.S74~S83 (2002)
- Makuuchi M, "Remodeling the surgical approach to hepatocellular carcinoma", Hepatogastroenterology, 49, pp.36~40 (2002)
- Nakazawa T, "Radiofrequency ablation of hepatocellular carcinoma : correlation between local tumor progression after ablation and ablative margin", AJR Am J Roentgenol, 188, pp.480~488 (2007)
- Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
- Marrero JA, "Prognosis of hepatocellular carcinoma : comparison of 7 staging systems in an American cohort", Hepatology, 41, pp.707~716 (2005)
- Kim JW, "Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller", Am J Gastroenterol, 109, pp.1234~1240 (2014)
- 조주연, "Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma", Clinical and Molecular Hepatology, 22(4), pp.477~486 (2016), 대한간학회[DOI]
- Bruix J, "Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
- Yu SJ, "A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world : 2010-2016", Clin Mol Hepatol, 22, pp.7~17 (2016)
- Lee EW, "Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma", Clin Mol Hepatol, 23, pp.265~272 (2017)
- Bruix J, "Management of hepatocellular carcinoma : an update", Hepatology, 53, pp.1020~1022 (2011)
- Forner A, "Current strategy for staging and treatment : the BCLC update and future prospects", Semin Liver Dis, 30, pp.61~74 (2010)
- Edge SB, "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)
- Gaba RC, "Transcatheter therapy for hepatic malignancy : standardization of terminology and reporting criteria", J Vasc Interv Radiol, 27, pp.457~473 (2016)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Kim BK, "Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma", J Hepatol, 62, pp.1304~1310 (2015)
- Vesselle G, "Predictive factors for complete response of chemoembolization with drug-eluting beads(DEB-TACE)for hepatocellular carcinoma", Eur Radiol, 26, pp.1640~1648 (2016)
- Ebied OM, "Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma", Cancer, 97, pp.1042~1050 (2003)
- Golfieri R, "Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?", J Vasc Interv Radiol, 24, pp.509~517 (2013)
- Terzi E, "TACE performed in patients with a single nodule of hepatocellular carcinoma", BMC Cancer, 14, pp.601~ (2014)
- Rou WS, "Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization", World J Gastroenterol, 20, pp.6995~7004 (2014)
- Kinugasa H, "Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma", J Gastroenterol, 47, pp.421~426 (2012)
- Kim JH, "Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area", J Gastroenterol Hepatol, 21, pp.588~594 (2006)
- Chang PE, "Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome", J Gastroenterol, 43, pp.881~888 (2008)
- Niederle IM, "Clinicopathologic features and prognosis of young patients with hepatocellular carcinoma in a large German cohort", J Clin Gastroenterol, 46, pp.775~778 (2012)
- Takeishi K, "Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy", World J Surg, 35, pp.1063~1071 (2011)
- Chen CH, "Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients", Liver Int, 26, pp.766~773 (2006)
- Cho SJ, "Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients?", J Gastroenterol Hepatol, 22, pp.1226~1231 (2007)
- Lam CM, "Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients : implications for screening", Aliment Pharmacol Ther, 19, pp.771~777 (2004)
- Yamazaki Y, "Hepatocellular carcinoma in young adults : the clinical characteristics, prognosis, and findings of a patient survival analysis", Dig Dis Sci, 52, pp.1103~1107 (2007)
- Ha SY, "The prognosis of hepatocellular carcinoma after curative hepatectomy in young patients", Oncotarget, 6, pp.18664~18673 (2015)
- Hsu CY, "Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria : a propensity score analysis", Liver Transpl, 17, pp.556~566 (2011)
- Bargellini I, "Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment : a prospective cohort study", Eur J Radiol, 81, pp.1173~1178 (2012)
- Takayasu K, "Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients", Gastroenterology, 131, pp.461~469 (2006)
- Hsu KF, "Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function", Eur J Radiol, 81, pp.466~471 (2012)
- Matsui O, "Small hepatocellular carcinoma : treatment with subsegmental transcatheter arterial embolization", Radiology, 188, pp.79~83 (1993)
- Song YG, "Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation : a retrospective cohort study of 116 patients", Acta Radiol, 56, pp.70~77 (2015)